Patent aggregation is one of the critical paths to raise revenue and earn a return on investment in the ICT sector. It comprises all activities whereby firms build sets of related patents, so-called patent portfolios, and subsequently use these beyond manufacturing. Different kinds of entities...
Constructing a functioning single market for business and trade among the Member States of the European Union (EU) has been the cornerstone of the EU project, and remains one of the strongest drivers for EU-level legislative reform. Over the years, the EU has prioritized the harmonization of...
The implementation of the Unitary Patent Package will represent the result of the evolution towards the unification of the European patent system.
Using the trade mark of someone else to describe how your own products relate to the trademark products is allowed under certain circumstances. Recently, the law changed in this respect, leaving the application of some factors uncertain.
The ongoing COVID-19 pandemic is arguably one of the biggest crises of modern times. The conflict between the search for a vaccine, and the artificial scarcity created by patent law, has created a catch-22 situation. How will patent law apply to a vaccine under these circumstances?
Several pharmaceutical companies all around the world, including in the European Union (EU), have been racing to find a treatment for the virus. Since these may be subject to patent rights, government intervention may be needed.
Electronics companies increasingly engage in patent aggregation, that is to accrue patents without using them for manufacturing purposes. So far, it is unclear whether such behaviour has negative effects on innovation. If it did, could EU competition law remedy it?
The quality of a granted patent is dependent on the quality of the patent application. For the companies where scientists write their own patents, IP legal training for scientists can help improving their patent drafting skills.
Unlike other sectors, improvements in Genetic technology raise issues of morality. The new human gene editing technology CRISPR/CAS9 has raised many such concerns. Can the current patent system deal with these concerns or should morality be dealt with by the inventors themselves?
On September 9th 2015 the president of the Commission, Juncker, adressed for his first time the European Parliament in his State of the Union. This year’s State of the Union was entitled: Time for Honesty, Unity and Solidarity. And the key concepts were: more Europe in the Union, and more Union in...
